These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Feb 20, 2015Agenus to Report Fourth Quarter and Year End 2014 Financial Results on February 26, 2015; Conference Call to Follow
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), will release its fourth quarter and year end 2014 financial results before the market opens on Thursday, February 26, 2015. Agenus...
Feb 3, 2015
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immunology company developing a series of immune-oncology checkpoint modulators (CPMs), heat shock protein peptide-based vaccines,...
Jan 9, 2015Alliance to initially focus on four checkpoint modulator programs directed at GITR, OX40, TIM-3 and LAG-3
Incyte Corporation (Nasdaq: INCY) and Agenus Inc. (Nasdaq: AGEN) today announced a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus’...
Jan 9, 2015Agenus to Host Conference Call to Discuss Global Alliance with Incyte Corporation Today at 8:30 a.m. EST
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN) will host a conference call today to discuss its global license, development and commercialization agreement with Incyte Corporation...
Dec 18, 2014GSK’s ZOE-50 Phase 3 study meets primary endpoint of reducing the risk of shingles in people aged 50 and older
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing a broad portfolio of checkpoint modulators (CPMs) and heat shock protein peptide-based vaccines as well as adjuvants, announced...